Eric R Blackstone

US Patent:

20080085329, Apr 10, 2008

Filed:

Aug 10, 2007

Appl. No.:

11/837484

Inventors:

Mark Roth - Seattle WA, US
Eric Blackstone - Seattle WA, US

Assignee:

Fred Hutchinson Cancer Research Center, Inc. - Seattle WA

International Classification:

A61K 33/04
A61K 31/095
A61K 31/10
A61P 43/00
A61K 33/00

US Classification:

424701000, 424699000, 424708000, 514706000, 514708000

Abstract:

The present invention concerns the use of oxygen antagonists for inducing stasis in cells, tissues, and/or organs in vivo or in an organism overall. It includes methods and apparatuses for achieving stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer is provided.

US Patent:

20080171093, Jul 17, 2008

Filed:

Aug 12, 2007

Appl. No.:

11/837536

Inventors:

Mark B. Roth - Seattle WA, US
Eric Blackstone - Seattle WA, US

Assignee:

Fred Hutchinson Cancer Research Center, Inc. - Seattle WA

International Classification:

A61K 33/00

US Classification:

424600

Abstract:

The present invention concerns the use of oxygen antagonists for inducing stasis in cells, tissues, and/or organs in vivo or in an organism overall. It includes methods and apparatuses for achieving stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer is provided.

US Patent:

20080171725, Jul 17, 2008

Filed:

Aug 10, 2007

Appl. No.:

11/837491

Inventors:

Mark B. Roth - Seattle WA, US
Mike Morrison - Seattle WA, US
Eric Blackstone - Seattle WA, US
Dana Miller - Seattle WA, US

International Classification:

A61K 31/66
A61K 31/555
A61K 31/185
A61K 31/165
A61K 31/275
A61K 31/26
A61K 31/095
A61K 31/21

US Classification:

514114, 514126, 514184, 514514, 514526, 514553, 514621, 514706

Abstract:

The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.

US Patent:

20080171726, Jul 17, 2008

Filed:

Aug 12, 2007

Appl. No.:

11/837539

Inventors:

Mark B. Roth - Seattle WA, US
Mike Morrison - Seattle WA, US
Eric Blackstone - Seattle WA, US
Dana Miller - Seattle WA, US

International Classification:

A61K 31/66
A61K 31/555
A61K 31/185
A61K 31/165
A61K 31/275
A61K 31/26
A61K 31/095
A61K 31/21
A61P 43/00

US Classification:

514144, 514126, 514184, 514514, 514526, 514553, 514621, 514706

Abstract:

The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.

US Patent:

20120040024, Feb 16, 2012

Filed:

Jul 29, 2011

Appl. No.:

13/194635

Inventors:

Mark B. Roth - Seattle WA, US
Mike Morrison - Seattle WA, US
Eric Blackstone - Seattle WA, US
Dana Miller - Seattle WA, US

International Classification:

A61K 33/04
A61P 7/00
A61P 9/10
A61P 9/00
C12N 5/07
A61P 43/00

US Classification:

424702, 435375

Abstract:

The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.

US Patent:

20070078113, Apr 5, 2007

Filed:

Apr 20, 2006

Appl. No.:

11/408734

Inventors:

Mark Roth - Seattle WA, US
Mike Morrison - Seattle WA, US
Eric Blackstone - Seattle WA, US
Dana Miller - Seattle WA, US

International Classification:

A61K 31/66
A61K 31/555
A61K 31/185
A61K 31/165
A61K 31/275
A61K 31/26
A61K 31/095
A61K 31/21

US Classification:

514114000, 514184000, 514706000, 514126000, 514553000, 514514000, 514526000, 514621000

Abstract:

The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.

US Patent:

20160361356, Dec 15, 2016

Filed:

Jan 11, 2016

Appl. No.:

14/992637

Inventors:

- Seattle WA, US
Mike Morrison - Seattle WA, US
Eric Blackstone - Seattle WA, US
Dana Miller - Seattle WA, US

International Classification:

A61K 33/04

Abstract:

The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.